Structurally guided therapy shows promise for patients with specific EGFR-mutated lung cancer in Phase 1b trial
Firmonertinib is an experimental therapy from ArriVent BioPharma for patients with EGFR PACC mutations
PACC mutations make up about 12% of EGFR-mutant non-small cell lung cancers, which make up 5-10% of all lung cancers
Results from this trial, which included intracranial responses in patients with brain metastases, initiated the ongoing Phase 3 ALPACCA trial
Researchers identified a potential biomarker...
AI model uses routine imaging to identify patients at risk for serious treatment-induced lung inflammation
Immunotherapy-induced lung inflammation is a potentially life-threatening condition that occurs in about 10% of lung cancer patients receiving...
First-in-class therapy targets “undruggable” protein in hard-to-treat blood cancers
The MYC protein is involved in about 70% of cancers, but scientists have been unable to develop drugs that effectively block it
Scientists uncover drivers of recurrent arthritis after immunotherapy, suggesting potential biomarkers
Some patients receiving immunotherapy can develop recurrent inflammatory arthritis that often worsens in subsequent flare-ups
Researchers identified immune cells that were present during both the initial and recurrent arthritis flares
Findings suggest that recurrent inflammatory arthritis behaves like an immune-memory disease, with the same immune cell populations expanding and becoming more aggressive over time</...
Immune cell dysfunction, not absence, defines skin cancer in immunosuppressed patients
Patients with weakened immune systems develop non-melanoma skin cancers that are more frequent, more aggressive, and more often lethal ...
Reshaping the gut microbiome can boost chemotherapy delivery to tumors
Nanoparticle-based chemotherapy is widely used but liver clearance often limits its effectiveness
The gut microbiome regulates...
Targeting a signaling pathway activated by acidic tumor environment restores treatment response to PARP inhibitors in ovarian cancer
PARP inhibitors are among the most widely used therapies for ovarian cancer, but their long-term effectiveness is limited by acquired resistance...
Epigenetic therapy shows promise against treatment-resistant AML
Next-generation epigenetic therapy showed stronger anti-leukemia activity than current standard treatments in preclinical models of acute...
Fasting primes gut microbiome to improve intestinal recovery after radiation treatment
Researchers identified a gut bacterium that helps prime intestinal stem cells for faster recovery
In preclinical models, short-term...
Biomarker-guided drug combinations may improve outcomes in treatment-resistant melanoma
In a preclinical study, adding a BCL2 inhibitor to standard melanoma therapy shrank tumors that had stopped responding to therapy
The study...
Study identifies a new cause of age-related inflammation, suggesting promising treatment pathway
As cells age, they increasingly export nucleic acid structures called R-loops from the nucleus, triggering an immune response that causes...